Please wait a minute...
浙江大学学报（医学版）
浙江大学学报（医学版）  2017, Vol. 46 Issue (4): 439-444    DOI: 10.3785/j.issn.1008-9292.2017.08.15
指南与实践     
不同量甲醛固定液对荧光原位杂交法检测乳腺原发性浸润癌HER2基因扩增的影响
陈志强, 王莹, 米贤军, 段立锋, 陈昂, 黄华勇
南方医科大学附属中山市博爱医院病理科, 广东 中山 528400
Volume of 4% neutral buffered formaldehyde affects the results of HER2 gene detected by fluorescence in situ hybridization in primary invasive breast cancer
CHEN Zhiqiang, WANG Ying, MI Xianjun, DUAN Lifeng, CHEN Ang, HUANG Huayong
Department of Pathology, Zhongshan Boai Hospital Affiliated to Southern Medical University, Zhongshan 528400, China
 全文: PDF(2603 KB)   HTML ( ) 
摘要：

目的：通过分析不同的体积量甲醛固定液对荧光原位杂交（FISH）法检测乳腺原发性浸润癌人类表皮生长因子受体2（HER2）基因扩增的差异，为建立和优化乳腺癌HER2基因扩增检测过程中的标本固定方法提供实验依据。方法：选取中山市博爱医院2014年6月至2016年10月手术切除乳腺原发性浸润癌109例，同一肿瘤病变部位切取组织七块，根据随机数字表分为A、B、C、D、E、F、G组。使用4%中性（磷酸盐缓冲）甲醛作为固定液，从A组到G组固定液量与所浸泡组织体积的比例分别为3：1、6：1、9：1、10：1、15：1、20：1、25：1，固定15 h后制作石蜡切片。采用FISH法检测HER2基因扩增，观察各组HER2基因扩增结果的差异。结果：在荧光显微镜下，A、B、C组的组织轮廓较模糊，出现细胞碎片，部分探针定位欠佳，出现信号丢失、核发空现象，见明亮的桔红/绿色荧光信号；D、E、F、G组的组织轮廓清晰而完整、背景洁净、探针定位准确，见耀眼的桔红/绿色荧光信号。A~D组基因扩增阳性率逐渐增高（χ2=8.601，P<0.01），D~G组基因扩增阳性保持稳定；固定液量与所浸泡组织体积的比例在10：1以下（A、B、C组）时，HER2基因扩增状态不稳定，随着固定液量的增加不断出现新的基因扩增阳性患者；固定液量与所浸泡组织体积的比例在10：1及以上（D、E、F、G组）时，HER2基因扩增阳性率稳定在24.77%；D、E、F、G组的基因扩增阳性率高于A、B、C组（均P<0.05）。结论：采用FISH法检测乳腺原发性浸润癌HER2基因扩增，固定液的量要保证至少是所浸泡组织体积的10倍以上方可获得确切而稳定的实验结果。
关键词： 乳腺肿瘤/病理学;  肿瘤浸润;  固定剂;  甲醛/投药和剂量;  原位杂交;  荧光;  受体;  表皮生长因子    
Abstract:

Objective:To investigate the effects of the volume of 4% neutral phosphate buffered formalin fixative solution on the detection of human epidermal growth factor receptor 2 (HER2) gene by fluorescence in situ hybridization (FISH) in primary invasive breast cancer. Methods:Tissue samples were collected from 109 patients with primary invasive breast cancer admitted in Zhongshan Boai Hospital from June 2014 to October 2016. The ratios of 4% phosphate buffered formalin fixative solution to sample volume samples were 3:1, 6:1, 9:1, 10:1, 15:1, 20:1 or 25:1 (groups A, B, C, D, E, F and G), respectively. Paraffin sections were made after 15 h of fixation. The amplification of HER2 gene was detected by FISH. The gene amplification results of HER2 were observed and compared in different groups. Results:Fluorescence microscope showed that the tissue contour in groups A, B and C was vague, cell debris appeared, and the probe was positioned poorly; while the tissue contour was clear and complete in groups D, E, F and G and the probe was positioned accurately. The positive rate of HER2 was gradually increased from group A to D(χ2=8.601, P<0.01), and that remained stable at 24.77% in groups D to G. The positive rate of gene amplification in groups D, E, F and G was significantly higher than that in groups A, B and C (all P<0.05). Conclusion:When using FISH to detect HER2 gene in samples of primary breast invasive carcinoma, the volume of fixative solution should be at least 10 times of the sample volume to obtain accurate and stable results.
Key words: Breast neoplasms/pathology    Neoplasm invasiveness    Fixatives    Formaldehyde/administration &    dosage    In situ hybridization, fluorescence    Receptor, epidermal growth factor
收稿日期: 2017-03-17 出版日期: 2017-08-25
CLC:  R446.6  
基金资助:

广东省医学科学技术研究基金（A2017321）；广东省中山市卫生和计划生育局医学科研立项课题（2014J128）
作者简介: 陈志强(1981-),男,学士,副主任技师,主要从事病理学技术研究;E-mail:765228687@qq.com
服务　　
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章　　

引用本文:

陈志强 等. 不同量甲醛固定液对荧光原位杂交法检测乳腺原发性浸润癌HER2基因扩增的影响[J]. 浙江大学学报（医学版）, 2017, 46(4): 439-444.

CHEN Zhiqiang, WANG Ying, MI Xianjun, DUAN Lifeng, CHEN Ang, HUANG Huayong. Volume of 4% neutral buffered formaldehyde affects the results of HER2 gene detected by fluorescence in situ hybridization in primary invasive breast cancer. Journal of ZheJiang University(Medical Science), 2017, 46(4): 439-444.

链接本文:

http://www.zjujournals.com/med/CN/10.3785/j.issn.1008-9292.2017.08.15    或    http://www.zjujournals.com/med/CN/Y2017/V46/I4/439

[1] LV Q X, MENG Z Y, YU Y Y, et al. Molecular mechanisms and translational therapies for human epidermal receptor 2 positive breast cancer[J]. Int J Mol Sci,2016,17(12):2095.
[2] 朱雄增.精准医学时代下的精准诊断[J].中华病理学杂志,2015,44(7):442-443. ZHU Xiongzeng. Precision diagnosis under prescision medicine[J]. Chinese Journal of Pathology,2015,44(7):442-443.(in Chinese)
[3] RAKHA E A, STARCZYNSKI J, LEE A H, et al. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer:a critical review of their implications for routine practice[J]. Histopathology,2014,64(5):609-615.
[4] 《乳腺癌HER2检测指南(2014版)》编写组.乳腺癌HER2检测指南(2014版)[J].中华病理学杂志,2014,43(4):262-267. Guideline Recommendations for HER2 Detection in Breast Cancer Group.Guidelines for HER2 detection in breast cancer, the 2014 version[J]. Chinese Journal of Pathology,2014,43(4):262-267. (in Chinese)
[5] WOLFF A C, HAMMOND M E, HICKS D G, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer:American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update[J]. Arch Pathol Lab Med,2014,138(2):241-256.
[6] 许燕,杨文涛,杨飞,等.双色银染原位杂交与荧光原位杂交在乳腺癌HER2基因状态评估中的比较[J].中华病理学杂志,2014,43(4):226-230. XU Yan, YANG Wentao, YANG Fei, et al. Assessment of HER2 gene amplification in breast cancer:a comparison of dual color in situ hybridization and fluorescence in-situ hybridization[J]. Chinese Journal of Pathology,2014,43(4):226-230. (in Chinese)
[7] KONG P L, LOOI L M, LAU T P, et al. Correction:assessment of telomere length in archived formalin-fixed, paraffinized human tissue is confounded by chronological age and storage duration[J/OL]. PLoS One,2016,11(12):e0168238.
[8] 步宏,杨文涛.以标准化的乳腺癌HER2检测带动病理诊断质量的提高[J].中华病理学杂志,2014,43(4):217-218. BU Hong, YANG Wentao. To improve the quality of pathologic diagnosis through standardized HER2 testing[J]. Chinese Journal of Pathology,2014,43(4):217-218. (in Chinese)
[9] 王银萍.病理专业医疗质量控制指标(2015年版)的解读[J].中华病理学杂志,2015,44(11):830-832. WANG Yinping. Interpretation of medical quality control index (2015 Edition) of pathology specialty[J]. Chinese Journal of Pathology,2015,44(11):830-832.(in Chinese)
[10] LAKHANI S R, ELLIS I O, SCHNITT S J, et al. WHO classification of tumours of the breast[M]. Lyon:IARC Press,2012.
[11] 中华医学会.临床技术操作规范病理学分册[M].北京:人民军医出版社,2012:33. Chinese Medical Association. The fascicle of clinic pathology regulation for technical operations[M]. Beijing:People's Military Medical Press,2012:33. (in Chinese)
[12] 陈志强,王莹,米贤军,等.聚羟基丙烯酸和4%中性缓冲甲醛对苏木精伊红染色及荧光原位杂交检测乳腺癌HER-2基因影响的比较[J].中国癌症杂志,2016,26(2):121-126. CHEN Zhiqiang, WANG Ying, MI Xianjun, et al. Comparison of the role that poly hydroxy acrylic acid plays in the detection of HER-2 gene in breast cancer by hematoxylin and eosin staining and fluorescence in situ hybridization with that of 4% neutral buffered formaldehyde[J]. China Oncology,2016,26(2):121-126. (in Chinese)
[13] STELLA P, LUCIA C, RACHELE S, et al. FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with unfavorable characteristics[J]. Oncol Lett,2016,12(5):3115-3122.
[14] 张虹,王双,王颖,等.运用2013版美国临床肿瘤学会/美国病理医师学院乳腺癌HER2检测指南对1501例浸润性乳腺癌的HER2状态进行再评估[J].中华病理学杂志,2015,44(1):42-47. ZHANG Hong,WANG Shuang,WANG Ying, et al. Re-evaluation of HER2 status in 1501 invasive breast cancers according to the 2013 American Society of Clinical Oncology/College of American Pathologist guidelines[J]. Chinese Journal of Pathology,2015,44(1):42-47. (in Chinese)
[15] 杨莹,魏兵,步宏.乳腺癌HER2检测的现状及存在的问题[J].临床与实验病理学杂志,2010,26(5):602-605. YANG Ying, WEI Bing, BU Hong. Current situation and problems of HER2 detection in breast cancer[J]. Chinese Journal of Clinical and Experimental Pathology,2010,26(5):602-605. (in Chinese)
[16] MOATAMED N A, NANJANGUD G, PUCCI R, et al. Effect of ischemic time, fixation time, and fixative type on HER2/neu immunohistochemical and fluorescence in situ hybridization results in breast cancer[J]. Am J Clin Pathol,2011,136(5):754-761.
[17] 《胃癌HER2检测指南(2016版)》专家组.胃癌HER2检测指南(2016版)[J].中华病理学杂志,2016,45(8):528-532. Guideline Recommendations for HER2 Detection in Gastric Cancer Group.Guidelines for HER2 detection in gastric cancer(2016)[J]. Chinese Journal of Pathology,2016,45(8):528-532. (in Chinese)
[1] 魏振龙, 石文贵, 陈克明, 周建, 王鸣刚. 淫羊藿素通过CXCR4/SDF-1信号通路促进小鼠成骨细胞成熟和矿化[J]. 浙江大学学报（医学版）, 2017, 46(6): 571-577.
[2] 潘静颖 等. PET-CT与乳腺癌分子病理分型、治疗反应及预后的相关性研究进展[J]. 浙江大学学报（医学版）, 2017, 46(5): 473-480.
[3] 董飞 等. 磁共振成像强化信号特征预测胶质母细胞瘤EGFR基因扩增状态的影像组学研究[J]. 浙江大学学报（医学版）, 2017, 46(5): 492-497.
[4] 王海凤 等. CXC趋化因子受体4通过S期激酶相关蛋白2调控乳腺癌细胞周期的机制[J]. 浙江大学学报（医学版）, 2017, 46(4): 357-363.
[5] 田华 等. CD97免疫表位对乳腺癌细胞株MDA-MB231生物学行为的影响[J]. 浙江大学学报（医学版）, 2017, 46(4): 341-348.
[6] 严恺 等. 出生缺陷相关遗传病产前诊断技术新进展[J]. 浙江大学学报（医学版）, 2017, 46(3): 227-232.
[7] 邹继霞 等. 肿瘤过继T细胞免疫治疗应用进展[J]. 浙江大学学报（医学版）, 2017, 46(2): 211-217.
[8] 何玉洁 等. 病原菌对NOD样受体及Toll样受体信号通路介导的固有免疫逃逸机制研究进展[J]. 浙江大学学报（医学版）, 2017, 46(2): 218-224.
[9] 邹继霞,章程燕,王苹莉. 肿瘤过继T细胞免疫治疗应用进展[J]. 浙江大学学报（医学版）, 2017, 46(2): 211-217.
[10] 刘馨刚 等. 氟硼二吡咯类光敏剂的制备及对肿瘤细胞的光动力学影响[J]. 浙江大学学报（医学版）, 2017, 46(2): 135-143.
[11] 何玉洁,潘建平. 病原菌对NOD样受体及Toll样受体信号通路介导的固有免疫逃逸机制研究进展[J]. 浙江大学学报（医学版）, 2017, 46(2): 218-224.
[12] 刘馨刚,吴敏,李素莹,李忠宝,胡青莲,周峻,汤谷平. 氟硼二吡咯类光敏剂的制备及对肿瘤细胞的光动力学影响[J]. 浙江大学学报（医学版）, 2017, 46(2): 135-143.
[13] 王颖,汪仪,陈忠. 中枢胆碱能系统与癫痫关系的研究进展[J]. 浙江大学学报（医学版）, 2017, 46(1): 15-21.
[14] 封盛 等. 糖皮质激素受体信号通路在膀胱癌治疗中的作用研究进展[J]. 浙江大学学报（医学版）, 2016, 45(6): 655-660.
[15] 夏光发 等. 新辅助化疗前后激素受体变化的乳腺癌患者辅助内分泌治疗的疗效[J]. 浙江大学学报（医学版）, 2016, 45(6): 614-619.